Table 5.
Independent prognostic factors for overall survival in HCC patients treated with sorafenib according to multivariate analysis
| Variables | HR | 95% CI | P value |
|---|---|---|---|
| ECOG PS 2–3 versus 0–1 | 2.01 | 1.60–2.77 | <0.001 |
| Child Pugh B versus A | 1.80 | 1.37–2.36 | <0.001 |
| Etiology of liver disease | |||
| None (Reference) | |||
| Hepatitis B | 0.87 | 0.64–1.13 | 0.26 |
| Hepatitis C | 0.61 | 0.46–0.83 | 0.001 |
| Alcohol‐related liver disease | 0.61 | 0.42–0.87 | 0.006 |
| Other/multiple | 0.63 | 0.45–0.88 | 0.007 |
| Extent of tumor within the liver | |||
| >50% versus <50% | 1.32 | 1.07–1.61 | 0.008 |
| AFP > ULN | 1.47 | 1.20–1.80 | <0.001 |
| Prior hepatic resection | 0.54 | 0.43–0.69 | <0.001 |
AFP, alpha‐fetoprotein; ECOG, Eastern Cooperative Group performance status; HCC, hepatocellular carcinoma; ULN, upper limit of normal.